Safety and Prognostic Impact of Early Treatment with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Acute Heart Failure.

Kenji YoshiokaYuya MatsueTetsuo YamaguchiTakeshi KitaiNobuyuki KagiyamaTakahiro OkumuraKeisuke KidaShogo OishiEiichi AkiyamaSatoshi SuzukiMasayoshi YamamotoShunsuke KurodaAkihiko MatsumuraKenzo Hirao

Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2020)

Early initiation of ACEIs/ARBs within 48 h of admission for hospitalized patients with AHF was not associated with adverse events and correlated with improved outcomes at 1 year from admission.

Keyphrases

angiotensin converting enzyme
angiotensin ii
acute heart failure
emergency department
heart failure
type diabetes
metabolic syndrome
combination therapy
atrial fibrillation
insulin resistance